Cancer Cachexia: Science | July 2026

Introduction:

Cancer-associated cachexia is a devastating syndrome characterized by loss of appetite, weight loss, and muscle wasting, affecting up to half of patients with lung cancer. This landmark study uncovers a previously unrecognized mechanism linking dietary fat, tumor-derived prostaglandin E2 (PGE2), and sensory nerve signaling to the development of cachexia.

Why was this study needed?

• The mechanisms driving cancer cachexia remain poorly understood.
• Current therapies have limited efficacy in preventing appetite loss and muscle wasting.
• Cachexia has traditionally been attributed to circulating inflammatory factors.
• The influence of dietary fat on cachexia progression has been unclear.
• New therapeutic targets are urgently needed to improve outcomes in cancer patients.

Results:

• A high-fat diet paradoxically worsened cachexia, increasing appetite loss and weight loss in mice with Lkb1-mutant lung cancer.
• Tumor-derived prostaglandin E2 (PGE2) activated local lung sensory nerves, driving cachexia through neural signaling rather than circulating inflammatory mediators.
• Blocking PGE2 production or silencing sensory neurons markedly reduced cachexia, identifying a novel therapeutic pathway.

Clinical Impact:

This study fundamentally changes our understanding of cancer cachexia by demonstrating that local tumor–nerve communication, rather than systemic inflammation alone, can drive appetite loss and wasting. It also raises important questions about the routine use of high-fat nutritional supplementation in selected patients with cancer cachexia.

Bottom Line:

Cancer cachexia is not solely a systemic inflammatory disorder. Tumor-derived PGE2 activates sensory nerves to promote cachexia, and targeting the PGE2–sensory neuron axis may represent a promising new therapeutic strategy for preventing cancer-associated weight loss.